An international multicenter,randomized,open-label,phase Ⅲ trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in un-Treated staged Ⅲ / Ⅳ follicular non-Hodgkin ’ s lymphoma .Final results of NCCTG N0489:Epratuzumab and rituximab ......